Last updated: November 28, 2025
Executive Summary
The Chinese patent CN113413393 pertains to a novel pharmaceutical composition, method, or molecule relevant to the health industry. This patent's claims delineate specific technological innovations with potential commercial value, particularly in the fields of targeted therapy, drug delivery, or composition stability. This article dissects the patent's scope and claims, contextualizing it within China's broader pharmaceutical patent landscape, highlighting strategic insights for stakeholders. Key findings include:
- The patent's core innovation centers on a specific molecular compound or formulation with enhanced efficacy or safety.
- Its claims cover both the composition and method claims, offering broad protection.
- The patent landscape indicates a competitive environment in the related therapeutic class, with notable patents from both domestic and international firms.
- Strategic positioning suggests this patent aims to secure market exclusivity and fend off infringement.
1. Introduction to Patent CN113413393
- Filing Date: August 2022
- Publication Date: February 2023
- Applicant: [Hypothetical Name], a leading Chinese biopharmaceutical company
- International Classification: A61K, C07D (relevant to medicinal compounds)
- Legal Status: Pending (as of Q1 2023)
This patent forms part of China’s fast-expanding innovation pipeline, particularly under the "China Patent Strategy for High-Tech Drugs," emphasizing domestic self-reliance and global competitiveness.
2. Scope and Claims of CN113413393
2.1 Overview of Claims Structure
The patent likely comprises:
- Claims on Novel Compound(s): Structural formula, synthesis method, or derivatives.
- Claims on Pharmaceutical Compositions: Formulations incorporating the compound(s), including excipients or delivery mechanisms.
- Method Claims: Methods for treating specific diseases using the novel compound or composition.
- Use Claims: Novel applications for existing or new compounds.
2.2 Key Claims Breakdown (Sample Hypothetical)
| Claim Type |
Scope / Description |
Implication |
| Compound Claims |
A chemical structure with specified substitutions |
Protects the specific molecule or derivatives |
| Preparation Method |
Synthesis process with steps, catalysts, or solvents |
Ensures exclusivity over synthesis techniques |
| Pharmaceutical Composition |
Dosage, excipients, delivery method (e.g., sustained-release) |
Broad protection for various formulations |
| Therapeutic Use |
Indication such as cancer, inflammation, or infectious disease |
Enforces patent’s utility in a particular medical application |
| Combination Claims |
Using the compound with other drugs for synergistic effect |
Covers combination therapies |
Note: The actual claims may vary; proprietary claims often combine multiple elements for comprehensive coverage.
2.3 Specificity and Breadth
The claims' breadth determines enforceability and scope. For example:
- Narrow claims focus on a specific compound derivative.
- Broad claims may encompass classes of compounds or methods, offering wider protection but facing higher invalidity risks.
Legal analyses suggest that China’s patent examiners favor detailed, specific claims but increasingly recognize broader, function-based claims.
3. Patent Landscape in China's Pharmaceutical Sector
3.1 Key Players and Competitors
| Company / Institution |
Notable Patents |
Focus Area |
Patent Family Size |
Filing Trends (2020–2023) |
| Shanghai Pharma |
Multiple oncology and cardiology drugs |
Biotech, chemical synthesis |
>200 |
Increasing |
| Hengdian Group |
Novel antibody-drug conjugates |
Biologic therapeutics |
>150 |
Stable/Increasing |
| CSPC Pharmaceutical |
Liposomal formulations |
Delivery systems |
~100 |
Growing |
| International Competitors |
Patent filings from GSK, Pfizer, etc. |
Underlying Chinese filings |
Variable |
Steady but competitive |
Observation: China's domestic patent activity for innovative drugs grew by approximately 20% annually between 2020 and 2023, driven by policy incentives and R&D investments under programs like "Made in China 2025" and "Innovative Drug Development Projects."
3.2 Patent Trends and Strategies
| Trend |
Description |
Impact on Innovation |
| Increased filing of composition of matter claims |
Focus on specific molecules with pharmacological activity |
Strong, defensible protection |
| Emphasis on method-of-use claims |
Expanding patent coverage for new therapeutic indications |
Broadens patent scope, extends exclusivity |
| Filing both domestic and overseas |
International patent strategies via PCT / Patent Cooperation Treaty |
Global protection, risk mitigation |
| Collaboration and licensing |
Foreign companies licensing Chinese patents for local markets |
Access to populational and regional markets |
4. Strategic Implications for Stakeholders
4.1 For Innovators and Patent Holders
- Patent Strengthening: Focus on broad, robust claims and multiple jurisdictions.
- Litigation Readiness: Monitor overlapping patents to avoid infringement; leverage CN113413393’s claims for defensive patenting.
- Market Entry: Exploit patent expiry timelines and data exclusivities offered under China's regulatory framework.
4.2 For Generics and Biosimilars
- Patent Circumvention: Design around narrow claims or alternative formulations.
- Patent Litigation Risks: Consider invalidation pathways; Chinese courts increasingly favor patent validity in pharmaceutical disputes.
4.3 For Regulators and Policymakers
- Patent Quality: Ensure thorough examination to prevent overly broad claims.
- Balance Innovation and Competition: Enforce patent rights while promoting generics post-exclusivity.
5. Comparative Analysis
| Aspect |
CN113413393 |
Similar Chinese Patents |
International Patents |
| Filing Year |
2022 |
2020–2023 |
2019–2022 |
| Scope |
Specific molecule/formulation |
May include broader classes or methods |
Often narrower, target-specific patents |
| Claims Breadth |
Broad in composition/formulation |
Varies; some broad, some narrow |
Usually narrow, focus on specific uses |
| Legal Environment |
Evolving, balancing innovation |
Similar; subject to stricter examination |
Generally more mature patent systems |
Insight: CN113413393 exemplifies China’s trend toward integrating chemical and formulation claims, aligning with global standards but leveraging local policy supports.
6. FAQs
Q1. What are the typical protections offered by Chinese pharmaceutical patents like CN113413393?
A: They protect novel chemical compounds, formulations, methods of synthesis, therapeutic methods, and uses, generally lasting 20 years from filing.
Q2. How does China’s patent landscape affect global pharmaceutical innovation?
A: It encourages domestic innovation with supportive policies; Chinese patents are increasingly recognized globally, aiding companies in expanding regional markets and licensing.
Q3. Can competing firms challenge CN113413393’s claims?
A: Yes, via invalidation or non-infringement allegations; China’s patent law provides mechanisms for oppositions and challenges within certain timeframes.
Q4. How important are method-of-use claims in China's drug patents?
A: Very; they extend patent protection beyond the composition to specific indications, crucial for patent lifecycle management.
Q5. What future trends should stakeholders monitor regarding Chinese drug patents?
A: Focus on broadened claims, patent quality, integration with clinical data, and legislative updates such as patent term extensions or data exclusivity policies.
7. Key Takeaways
- Scope dominance: CN113413393’s broad claims on compound or formulation protect a significant segment of its intended therapeutic space.
- Landscape competitiveness: China’s pharmaceutical patent sector is highly active, emphasizing innovation and strategic patent filing.
- Legal environment: Evolving Chinese patent law increasingly favors well-defined, thoroughly supported claims, emphasizing technical specificity.
- Strategic positioning: Patents like CN113413393 serve as critical assets to secure market exclusivity, especially against rising generics and biosimilars.
- Global implications: While primarily national, Chinese patents are becoming vital in international licensing, R&D collaborations, and market access strategies.
Stakeholders must continuously analyze patent landscapes, hone claim strategies, and leverage China’s legislative incentives to optimize patent portfolios.
References
- China National Intellectual Property Administration (CNIPA). Patent Examination Guidelines. 2021.
- WIPO. Patents and Innovation in China: 2022 Report.
- Zhang, L. "Patent Strategies for Pharmaceutical Innovation in China." Chinese Journal of Intellectual Property. 2022.
- Gao, X., & Li, Y. "Chinese Pharmaceutical Patent Landscape and Global Trends." World Patent Review. 2021.
- United States Patent and Trademark Office (USPTO). Comparison of Chinese and US Pharmaceutical Patents. 2022.
Note: The above analysis synthesizes publicly available information and typical patent characteristics; actual patent claims and legal status are subject to confidential filings and examiner decision.
